Abstract
Age-related changes occur in all structures of the eye causing varied effects. With ageing, lens opacities and changes in the vitreous occur and the vitreous gel undergoes liquefaction. A number of changes occur in the retina including accumulation of lipofuscin, thickening of Bruch’s membrane, narrowing of the choroidal arteries and accumulation of material forming soft drusen. The four main causes of low or loss of vision are age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. The pathophysiology of AMD is complex and unclear, and the pathological processes implicated are accumulation of lipofuscin, formation of drusen, neovascularisation and inflammation. Complement system plays a vital role in the pathology of AMD. In glaucoma, elevated intraocular pressure and vascular dysfunction are said to contribute to initial insult and the ultimate result is death of the retinal ganglion cells causing irreversible visual loss. Cataract of old age is multifactorial with genetic, environmental and biochemical factors which act synergistically. A number of biochemical pathways have been proposed as possible links between hyperglycaemia and diabetic retinopathy (DR). The instrumental pathways include increased polyol pathway, activation of protein kinase C and increase exposure of growth factors such as vascular endothelial growth factor (VEGF).
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Salvi SM, Akhtar S, Currie Z. Ageing changes in the eye. Postgrad Med J. 2006;82:581–7.
Cassim R. The ageing eye. CME. 2007;25(10):484–9.
Niesel P. Visible changes of the lens with age. Trans Ophthalmol Soc UK. 1982;102:327–30 (abstract).
van den Berg TJTP, van Rijn LJ (Rene), Kasper-Bongers R, et al. Disability glare in the aging eye. Assessments and impact on driving. J Optom. 2009;02(03):112–8.
Ducan G, Weale RA. Physical changes due to aged cataracts. In: Ducan G, editor. Mechanisms of cataract formation in the human lens. London: Academic Press; 1981. p. 47–70.
Boniha VL. Age and disease-related structural changes in the retinal pigment epithelium. Clin Ophthalmol. 2008;2(2):413–24.
Sarks J, Sarks S. Age related macular degeneration. Australian doctor. 28 Sept 2001.
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82:844–85.
National Eye Institute. Facts about Age-related macular degeneration [NEI Health Information]. http://www.nei.nih.gov/health/maculardegen/armd_facts.asp.
Macular Degeneration Foundation 2007. Is anything more precious than your sight? Macular Degeneration Foundation. http://www.mdfoundation.com.au.
de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:4474–785.
Wikipedia Macular degeneration. http://en.wikipedia.org/wiki/Macular_degeneration.
Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353–63.
Zarbin MA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol. 1998;8(4):199–206 (abstract).
Nita M, Strzalka-Mrozik B, Grzybowski A, Mazurek U, Romaniuk W. Age-related macular degeneration and changes in the extracellular matrix. Med Sci Monit. 2014;20:1003–16 (abstract).
Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course and laser photocoagulation-induced regression. Surv Ophthalmol. 1999;44(1):1–29 (abstract).
Arnold JJ, Sarks SH. Age related macular degeneration. BMJ. 2000;321:7263–741.
Pauleikhoff D. Drusen in Bruch’s membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration. Ophthalmologe. 1992;89(5):363–86 (abstract).
Lutty G, Grunwalde J, Majji AB, Uyama M, Yoneya S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis. 1999;5:35 (abstract).
Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane and retinal pigment epithelium in postmortem eyes with age –related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999;44 Suppl 1:S10–32 (abstract).
Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. International Age-Related Maculopathy. Epidemiological Study Group. An International classification and Age-Related Maculopathy and Age-Related Macular Degeneration. Surg Ophthalmol. 1995;39:367–74.
Macular Photocoagulation Study Group. Subfoveal neovascular lesion image-related ADM. Guidelines for evaluation and treatment in macular photocoagulation study. Arch Ophthalmol. 1991;109:1242–51.
Bhutto IA, McLead DS, Hasegawa T, Kim SY, Merges C, Tong P, et al. Pigment epithelium – derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid eyes with age related macular degeneration. Exp Eye Res. 2006;82(1):99–110.
Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol. 2012;40(1):18–26.
Broadhead GK, Chang A, McCluster P. Genetics in age-related macular degeneration: current research and implications for future treatment? Asia Pac J Ophthamol. 2012;5:312–8.
Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melborne Visual Impairment Project. Ophthalmology 1998;105(4):733–9.
Kumarasamy NA, Lam FS, Wong AL, Theoharides TC. Glaucoma: current and developmental concepts for inflammation, pathways and treatment. Eur J Inflammation. 2006;41(3):129–37.
Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS, et al. Current concepts in the pathogenesis of glaucoma. Ind J Ophthalmol. 2001;57(4):257–66.
Dimitriou D, Broadway DC. Pathophysiology of glaucoma. In Glaucoma: basic and Clinical perspectives. 2013. p. 32–57. http://www.futuremedicine.com/doi/abs/10,2217/ebo.12420.
Kanshik S, Pandau SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003;49:90–5.
Australian Institute and Health Welfare (AIHW). http://www.aihw.gov.au/workArea/Download.Assit.aspx?id+6442453390. Accessed 10 Jan 2015.
Chitkara DK, Hall AB, Rosenthal AR. Pathology and epidemiology of cataract. Section 2-Cataract. Ophthamology; 2010:269–72. Chap 35.
Wegener A. Pathophysiology of cataract. 98th annual meeting DOG 2000. http://www.dog.org/2000/e_abstract_2000/214html.
Schmitt C, Hockwin O. The mechanisms of cataract formation. J Inher Metab Dis. 1990;13:501–8.
Kempen JH, O’Colman BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in US. Arch Ophthamol. 2004;122(4):552–63 (abstract).
Access my library. Pathophysiology of diabetic retinopathy. Optician.http://www.accessmylibrary.com/coms2/summary_0286-18736025_ITM. Accessed 29 June 2008.
Garner A. Developments in the pathology of diabetic retinopathy: a review. J Roy Soc Med. 1981;74:427–31.
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. Ophthalmology; 2013. doi:http://dx.dorg/10.1155.2013/343560.
Mathews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood control in type 2 diabetes mellitus. cUKPDS 69. Arch Ophthalmol. 2004;122(1):1631–40.
Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27(6):608–21 (abstract).
Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6(4):511–24 (abstract).
Giese MJ, Speth RC. The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease. Pharmacol Thera. 2014;142(1):11–32.
Simo R, Hernandez C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32(8):1556–62.
Takagi H, Watanabe D, Suzuma K, Kurimoto M, Suzuma I, Ohashi H, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2007;77 Suppl 1:S62–4 (abstract).
Takagi H. Aging and retinal vascular diseases. Nihon Ganka Gakkai Zasshi. 2007;111(3):207–30 (abstract).
Fong DS, Aiello L, Gardner TW, King GI, Blankenship G, Cavallerano JD, et al. Diabetic retinopathy. Diabetes Care. 2003;26:S99–102.
Sino R, Carrasco E, Garcia-Ramirez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabet Rev. 2006;2:71–98.
Author information
Authors and Affiliations
Appendices
Multiple Choice Questions
-
1.
In aged-related macular degeneration (AMD), the following pathological changes that occur are true, EXCEPT:
-
A.
Dysfunction of retinal pigment epithelium (RPE) occurs early.
-
B.
Membranous debris accumulates on either side of the RPE.
-
C.
Membranous debris is believed to be lipoprotein derived and the lipoproteins are dietary and systemic.
-
D.
Soft drusen are larger and tend to be confluent.
-
A.
-
2.
The following are true in aged-related macular degeneration (AMD), EXCEPT:
-
A.
Focal pigmentation and systemic hypertension increase risk of developing choroidal neovascularisation (CNV).
-
B.
Hard drusen pose a low rate of CNV.
-
C.
Progression to CNV results from angiogenic factors such as vascular endothelial growth factor (VEGF).
-
D.
Complement system plays an important role in the pathogenesis of AMD.
-
A.
-
3.
The following are true of diabetic retinopathy (DR), EXCEPT:
-
A.
There is a close association between chronic hyperglycaemia and development and progression of DR.
-
B.
Macular oedema always occur early in DR.
-
C.
Vascular endothelial growth factor (VEGF) plays an important role in ischaemic retinal vascularisation.
-
D.
Microvascular leakage and microvascular occlusion are responsible for the development of DR.
-
A.
-
4.
The following statements are true in glaucoma, EXCEPT:
-
A.
In acute angle close glaucoma in certain situations of pupillary dilatation, the flow of aqueous is obstructed.
-
B.
Normal tension glaucoma causes visual field loss due to nerve damage.
-
C.
Elevation of the intraocular pressure (IOP) is a primary risk factor for the development of glaucoma.
-
D.
The ultimate result of glaucoma is irreversible visual loss.
-
A.
Answers to MCQs
1 = C; 2 = B; 3 = B; 4 = C
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2016). Low and Loss of Vision in the Elderly. In: Diseases in the Elderly. Springer, Cham. https://doi.org/10.1007/978-3-319-25787-7_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-25787-7_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-25785-3
Online ISBN: 978-3-319-25787-7
eBook Packages: MedicineMedicine (R0)